Primaquine

Primaquine is a medication that belongs to the class of 8-aminoquinoline drugs. It has been used for over 60 years in the treatment of malaria caused by Plasmodium vivax and Plasmodium ovale, which are the two most common types of malaria parasites that affect humans. In addition to its use in the treatment of malaria, primaquine has also been used as a prophylactic agent for travelers and military personnel who are at risk of contracting malaria. One of the unique features of primaquine is its ability to kill the dormant liver stage of the malaria parasite, called hypnozoites. This characteristic makes it a key drug in the elimination of malaria, as it can prevent the relapse of the infection several weeks or months after initial treatment. However, primaquine can cause some adverse effects, particularly in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a genetic condition that affects the red blood cells. This deficiency can cause hemolytic anemia, a condition where red blood cells are destroyed faster than they are produced. As such, individuals with G6PD deficiency must be screened before being given primaquine. In summary, primaquine is an important drug for the treatment and prevention of malaria, especially in endemic areas of Plasmodium vivax and Plasmodium ovale, and it is an essential tool in the fight against malaria. However, its use requires careful consideration to avoid adverse effects in individuals with G6PD deficiency.